SCY-635: Phase IIa data

Scynexis reported data from a double-blind, placebo-controlled, U.S. Phase IIa trial in 10 patients showing that twice-daily 300 mg oral SCY-635 plus standard of care (SOC; peginterferon alfa-2a and r...